Literature DB >> 24227902

Sudden clinical course of an unusual ENT tumour: clinical pictures of extramedullary plasmacytoma secondary to multiple myeloma.

F Pagella1, P Canzi, E Matti, M Benazzo.   

Abstract

Extramedullary plasmacytoma (EMP) is a rare monoclonal plasmacytic proliferation involving upper airways in 80% of cases. The heterogeneous pattern of frequency in the head and neck area may result in insidious clinical expressions that are potentially lethal for the patient. The presentation and management of two suggestive clinical photographs characterized by sudden and aggressive EMP development secondary to multiple myeloma are discussed.

Entities:  

Keywords:  Extramedullary plasmacytoma; Head and neck; Sudden clinical course

Mesh:

Year:  2013        PMID: 24227902      PMCID: PMC3825039     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


Introduction

Extramedullary plasmacytoma (EMP) is a rare monoclonal plasmacytic proliferation occurring in an extraskeletal site . EMP comprises 3-5% of all plasma cell neoplasms and accounts for less than 1% of all malignant head and neck tumours . The upper airways are involved in 80% of cases, although the heterogeneous pattern of frequency leads to consider exceptional some of the specific sites where the disorder appears . Its natural history is still unpredictable: EMP tends to be solitary, or it may be multiple at diagnosis in 10% of patients ; it may occur at disease onset (15-20%) or develop (15%) in course of multiple myeloma (MM) . Depending on the mass effect of the neoplasm, the clinical features are linked to the site of the illness, tumour size and involvement of the surrounding structures. As EMP does not show either distinctive clinical or radiologic features , diagnosis is provided by deep biopsies, and a multidisciplinary haematological approach is mandatory to complete the diagnostic-therapeutic work-up. The marked sensitivity to irradiation has led to consider radiotherapy the elective treatment, but up to now both a widely accepted consensus and an international guideline are still missing -. The presentation and management of two suggestive clinical pictures characterised by unusual and sudden development are discussed herein.

Case series

Case 1

A 74-year-old Caucasian male with a 3-year pre-existing stage I IgGk multiple myeloma (MM), came to our attention due to acute onset of diplopia with daily retro-orbital headache. Magnetic resonance imaging (MRI) and computerized tomography (CT) scans showed a left sphenoid sinus mass with ipsilateral cavernous sinus invasion, superior extension to the sinus roof, clivus erosion and imprint of the pituitary gland. Carotid artery impairment without lumen damage was also described (Figs. 1, 2). Fiberscope nasal inspection revealed only diffuse mucosal crusting without any evidence of tumour. After transnasal endoscopic sphenoidotomy, a biopsy of the lesion was performed: the histopathologic study was consistent with the diagnosis of EMP. No lytic lesions were found by bone radiograph survey. Bone marrow plasmacytosis was 30%. After radio-chemotherapy, complete regression of the tumour was achieved. The patient died 8 months later due to an intestinal perforation, without evidence of local or systemic relapse.
Fig. 1.

T1-weighted MRI with intravenous gadolinium enhancement showing a left sphenoid sinus mass with homogeneous contrast enhancement.

Fig. 2.

CT-scan without contrast of the same patient showing a homogeneous mass of the left sphenoid sinus extending into the middle cranial fossa.

T1-weighted MRI with intravenous gadolinium enhancement showing a left sphenoid sinus mass with homogeneous contrast enhancement. CT-scan without contrast of the same patient showing a homogeneous mass of the left sphenoid sinus extending into the middle cranial fossa.

Case 2

A 62-year-old Caucasian woman was presented with a previous medical history significant for stage IIIa IgGλ MM that completely resolved after chemotherapy (bortezomib plus dexamethasone). Two years later the patient developed lung, chest-wall and vertebral relapses. Due to marked dysphonia, she was submitted to head and neck CT with evidence of a left hemilaryngeal mass extended from pharyngoepiglottic fold to the paraglottic homolateral area. Thyroidal shield was not involved and a normofunctional goiter was also observed. Bone marrow biopsy identified a plasma cell infiltration of 50-60%. Chemo- and radiotherapy led to a complete regression of the disease except for the laryngeal involvement. Neck imaging did not demonstrate any treatment response and a rapid progressive dysphagia plus dyspnoea quickly addressed the patient to ENT evaluation. Upper airway endoscopy showed a smooth red mass probably originating from the left aryepiglottic area and extended to the glottic region, piriform sinus, pharyngoepiglottic area. Cricoarytenoid motility was absent and the airway was severely compromised (Fig. 3). Emergency transisthmic tracheostomy unexpectedly revealed a pathologic tissue inside the thyroid gland. Laryngeal and thyroidal biopsies detected extramedullary spreading of MM. Despite chemotherapy, the patient died two months later due to the EMP.
Fig. 3.

Endoscopic finding of a smooth red mass involving the left hemilarynx and extending to the ipsilateral piriform sinus.

Endoscopic finding of a smooth red mass involving the left hemilarynx and extending to the ipsilateral piriform sinus.

Discussion

The common EMP presentation in the upper airways strongly relates to the importance of ENT examination. The heterogeneous pattern of frequency in the head and neck area may result in insidious clinical expressions that are potentially lethal. In their review of 400 publications, Alexiou et al. point out the topographic preference of EMP. The occurrence in the sphenoid sinus (2.0%), larynx (11%) and thyroid gland (1.4%) is confined to very few cases, indeed considered rare, but the finding of a cavernous sinus syndrome and upper airway blockage is exceedingly rare -. These dramatic clinical complications reflect a highly aggressive tumour where any predictions about its natural history remain difficult. Classified as secondary or primary depending on whether there is evidence of systemic MM or not, EMP might suggest the presence of disseminated disease, and a multidisciplinary haematological evaluation is mandatory to exclude myelomatous lesions . Developing late in course of MM, both described cases share the same rapid extramedullary growth with a different and independent progression from MM. Extramedullary MM spreading is commonly associated with poor outcome, and the survival rate strictly depends on the myelomatous behaviour, chemotherapy side effects and any comorbid disorders. In our experience, the watershed of the prognostic perspectives was defined by EMP clinical progression rather than by MM growth. In the first case, an unexpected EMP lesion extending into the middle cranial fossa occurred in the context of a pre-existing stationary stage I MM, under no therapy. In the second patient, relapses of a stage III MM appeared with an extramedullary involvement of two crucial structures of the respiratory tree. Whereas myelomatous lesions resolved completely after chemoradiotherapy, EMP expanded, regardless of MM. This led to a severe dyspnoea and a subsequent emergency tracheostomy was required. Currently, there are no criteria to predict the sudden appearance of EMP during the course of MM. Its pathophysiology is poorly understood: EMP and MM might be considered two independent entities but simultaneous expressions of a unique disease, with different plasma cell families following a different natural history.

Conclusions

Despite the exceptionality of the two cases described, careful follow-up is recommended in patients with a history of MM, with particular regard to ENT symptoms. Long-term and well-controlled MM does not exclude the development of a highly aggressive EMP with sudden clinical course. Non-specific clinical and radiological presentations stress the importance of a multidisciplinary approach to achieve early correct diagnosis and prompt treatment.
  13 in total

1.  Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.

Authors:  Richard Soutar; Helen Lucraft; Graham Jackson; Anthony Reece; Jenny Bird; Eric Low; Diana Samson
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

2.  Extramedullary plasmacytoma of the nasal sinus cavities.

Authors:  Paul E Lomeo; John E McDonald; Judith Finneman
Journal:  Am J Otolaryngol       Date:  2007 Jan-Feb       Impact factor: 1.808

3.  Extramedullary plasmacytoma of paranasal sinuses. A combined therapeutic strategy.

Authors:  G Attanasio; M Viccaro; M Barbaro; E De Seta; R Filipo
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-04       Impact factor: 2.124

4.  Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts.

Authors:  C Alexiou; R J Kau; H Dietzfelbinger; M Kremer; J C Spiess; B Schratzenstaller; W Arnold
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

Review 5.  Multiple myeloma with extramedullary disease.

Authors:  Albert Oriol
Journal:  Adv Ther       Date:  2011-11-11       Impact factor: 3.845

6.  Plasmacytoma and upper airway obstruction.

Authors:  G S Yacoub; B A Dubaybo
Journal:  Am J Otolaryngol       Date:  1999 Jul-Aug       Impact factor: 1.808

7.  [Extramedullary plasmocytoma (EMP) of the head and neck: a series of 22 cases].

Authors:  F Tesei; U Caliceti; G Sorrenti; A Canciullo; E Sabbatini; S Pileri; S Neri; G Frezza; A Rinaldi Ceroni
Journal:  Acta Otorhinolaryngol Ital       Date:  1995-12       Impact factor: 2.124

8.  CT and MR imaging of solitary extramedullary plasmacytoma of the nasal tract.

Authors:  Alex Sik-Chung Ching; James Boon-Kheng Khoo; Vincent Fook-Hin Chong
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

9.  [Plasmacytomas of the head and neck].

Authors:  E Marzetti; A Marzetti; O Palma; R W Pezzuto
Journal:  Acta Otorhinolaryngol Ital       Date:  1996-02       Impact factor: 2.124

10.  Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years.

Authors:  J Bladé; R A Kyle; P R Greipp
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

View more
  1 in total

1.  Relapse of Multiple Myeloma Presenting as Lower Lip Numbness.

Authors:  Yusra M Al-Riyami; Abdulaziz Bakathir; Khalil Al-Farsi; Faisal Al-Azri
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.